Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa

1 Nov 2016

Abstract excerpt

Importance: Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating, often fatal, inherited blistering disorder caused by mutations in the COL7A1 gene encoding type VII collagen. Support and palliation are the only current therapies. Objective: To evaluate the safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with RDEB. Design, Setting, and Participants:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Dermatological and Skeletal Disorders
Share to Skin and Cellular Biology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27802546
DOI: 10.1001/jama.2016.15588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis BullosaPMID 27802546Read ↗

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosaSemantic proximity Read ↗

Correction of dog dystrophic epidermolysis bullosa by transplantation of genetically modified epidermal autografts.Semantic proximity Read ↗

Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin TissueSemantic proximity Read ↗

Gene Therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.Semantic proximity Read ↗

Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEBSemantic proximity Read ↗

Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissueSemantic proximity Read ↗

Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin GraftsSemantic proximity Read ↗

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.Semantic proximity Read ↗

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.